BioNTech’s Bold Pivot: From Pandemic Triumph to Cancer Research Frontier
BioNTech, known for its Covid-19 vaccine, is transitioning towards mRNA-based cancer therapies aiming for market approval by 2026. The company's earnings per share fell to €1.08, surpassing market forecasts, while…